根据种族/种族,非精子瘤丸癌患者的生存率差异
Reha-Baris Incesu1, Francesco Barletta2, Stefano Tappero3
1Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Cancer epidemiology
|February 20, 2024
概括
丸癌特异性死亡率 (CSM) 在非高加索男性非精子瘤中较高. 这种增加的风险因种族/种族和癌症阶段而异,影响不同患者群体的治疗策略.
科学领域:
- 在瘤学瘤学.
- 癌症流行病学 癌症流行病学
- 健康差异 在健康上的差异
背景情况:
- 历史数据表明,非高加索种族/种族与非精子瘤病例中较高的丸癌特异性死亡率 (CSM) 有关.
- 目前尚不清楚这种差异是否延伸到特定的非高加索人群,如西班牙裔,亚裔或非裔美国人.
研究的目的:
- 调查非高加索种族/族群的当代非精髓瘤患者是否与高加索人相比经历了更高的CSM.
- 分析基于种族/种族的非血红色的I,II和III阶段的CSM差异.
主要方法:
- 利用了2004-2019年间的监测,流行病学和最终结果 (SEER) 数据库.
- 采用卡普兰-梅尔图和多变量考克斯回归模型.
- 根据癌症阶段 (I,II,III) 进行分层分析,并根据第三阶段的预后因素进行调整.
主要成果:
- 在所有13,515名非精髓瘤患者中,非白种人始终表现出高于白种人的CSM.
- 种族/种族独立预测西班牙裔在所有阶段 (I,II,III) 的CSM.
- 非洲裔美国人在I和III阶段表现出更高的CSM,而亚洲人仅在III阶段表现出更高的CSM.
结论:
- 非高加索种族/族裔与非血性CSM的增加有关,但规模在不同群体之间有很大的差异.
- 西班牙裔在各个阶段都面临CSM升高,非裔美国人在I和III阶段,亚裔在III阶段.
- 这些种族/种族特异性发现对于个性化患者管理和未来临床试验设计至关重要.
相关概念视频
Cancer Survival Analysis
346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
Comparing the Survival Analysis of Two or More Groups
186
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
186
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K


